Grant: Project Grant
Ontario Institute for Cancer Research (Toronto, Ontario)
$1,147,500.00
The evolution of prostate cancer
FY 2017-18
Summary
Cancers are believed to start from a single mutated cell. That cell continues to divide and accumulate new mutations. Some of those mutations create a growth advantage, and as a result cancer cells continually evolve to be more and more aggressive. But the cancer cells will also meet selective pressures, like lack of nutrients or oxygen. Again, additional mutations will help the cells adapt and continue to grow and expand. But how many different types of tumour cells exist at diagnosis? And does the diversity caused by this evolutionary process influence the way cancers should be treated? We will use new DNA sequencing and computational techniques in prostate cancer to help address these questions, and improve treatment options.
Department
Program
Project Grant
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
368657
Name
Boutros Paul C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
The evolution of prostate cancer
Programtype2
Operating Grants
Orgnameinp2
Ontario Institute for Cancer Research (Toronto, Ontario)
Cihramount2
$1,147,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Biomarkers; Computational Biology; Dna Sequencing; Genomics; Machine-Learning; Phylogeny; Prognosis; Prostate Cancer; Subclonal Reconstruction
Abstract
Cancers are believed to start from a single mutated cell. That cell continues to divide and accumulate new mutations. Some of those mutations create a growth advantage, and as a result cancer cells continually evolve to be more and more aggressive. But the cancer cells will also meet selective pressures, like lack of nutrients or oxygen. Again, additional mutations will help the cells adapt and continue to grow and expand. But how many different types of tumour cells exist at diagnosis? And does the diversity caused by this evolutionary process influence the way cancers should be treated? We will use new DNA sequencing and computational techniques in prostate cancer to help address these questions, and improve treatment options.
Competitiondate
201709
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Boutros, Paul C
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,147,500~ $0~